Trial Profile
A Phase II Trial of PS-341 in Patients With Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 01 Mar 2006 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.